Story

Latigo Biotherapeutics Surges 17% in Market Debut After Upsized $346M IPO

ENTHMSVIIDZHZH-TWJAKOHI
Aug 7, 20261 min read
Latigo Biotherapeutics Surges 17% in Market Debut After Upsized $346M IPO
Text size
Background

Latigo Biotherapeutics Inc. (NASDAQ: LTGO) shares surged 17% in their trading debut Friday after the clinical-stage biopharmaceutical company raised $345.6 million in an upsized initial public offering priced at the top of its expected range.

Upsized Offering Details

The Thousand Oaks, California-based company sold 19.2 million shares at $18 each, according to a company statement. The final pricing came in at the high end of its marketed range of $16 to $18 per share. The offering was also larger than the 16 million shares Latigo had originally planned to sell, indicating robust investor interest.

Underwriters for the deal have a 30-day option to purchase up to an additional 2.88 million shares at the public offering price, less commissions. The offering is expected to close on August 10, subject to customary closing conditions.

Market Performance

Sample IUX Markets – In-articleAd

Shares began trading on the Nasdaq Global Select Market under the ticker symbol LTGO, opening at $21 per share. Based on the number of outstanding shares listed in its prospectus, the offering gives Latigo a market capitalization of approximately $1.3 billion.

Company Focus and Pipeline

Latigo Biotherapeutics, backed by Blue Owl Capital Inc., is focused on developing non-opioid analgesics for pain management. The company's pipeline aims to address the need for effective pain relief without the addiction risks associated with opioids.

Its lead product candidate, LTG-001, is an oral Nav1.8 inhibitor being developed for the treatment of acute pain. Goldman Sachs & Co. LLC, Jefferies, Leerink Partners, and Guggenheim Securities served as the joint book-running managers for the offering.

Read next

More on Stocks
Back to latest news

LATEST